Intravitreal anti-VEGF therapy is an important treatment option for patients with vision loss due to abnormal neovascularization, including AMD, macular edema secondary to retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and retinopathy of prematurity (ROP). Here, VEGFA is linked to diabetic macular edema.